Key Points
Sept 29 (Reuters) - Shares of Structure Therapeutics (GPCR.O) soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study...
The once-daily drug helped participants reduce up to 4.5 kgs of body weight on average after four weeks of treatment, the company said...
The drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's (NOVOb.CO) blockbuster weight-loss drug Wegovy and Eli Lilly's (LLY.N) diabetes drug Mounjaro...
Structure has said it is focused on developing oral obesity drugs that are simpler to manufacture than the current injectables...
Structure "delivered better-than-expected efficacy and tolerability" for its oral drug, said Leerink Partners Research analyst David Risinger, adding that the early data was exceptional...
